Navigation Links
Amylin and Takeda Announce Decision to Advance Development of Pramlintide/Metreleptin Combination Treatment for Obesity
Date:2/22/2010

lization agreement, have decided to halt further development of davalintide at this time.

About Obesity

Obesity is a chronic disease that affects over 400 million people worldwide and is linked to increased health risk of several medical conditions. According to The Obesity Society, obesity is the second leading cause of preventable death in the United States. The total direct and indirect cost attributed to overweight and obesity health issues exceeds $140 billion in the United States each year. Obesity is also rapidly becoming a major health problem in industrialized nations and many developing countries.

About Amylin Pharmaceuticals

Amylin Pharmaceuticals is a biopharmaceutical company dedicated to improving lives of patients through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide) injection. Amylin's research and development activities le
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Amylin Pharmaceuticals to Webcast Year-End Financial Results
2. Amylin Highlights 2010 Corporate Priorities at J.P. Morgan Healthcare Conference
3. Amylin Pharmaceuticals to Present at the 18th Annual Credit Suisse Healthcare Conference
4. Amylin Pharmaceuticals and Eli Lilly and Company Statement on FDAs BYETTA(R) (Exenatide) Injection Update
5. Amylin Pharmaceuticals Reports Third Quarter Financial Results
6. Amylin Pharmaceuticals Highlights New Data Supporting Therapeutic Potential of Obesity Pipeline at Obesity 2009
7. Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly
8. Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society
9. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
10. Takeda Announces Initiation of Trial to Study the Concomitant Use of Dexlansoprazole and Other Proton Pump Inhibitors with Plavix(R) (clopidogrel bisulfate)
11. Emerging Agents from Theravance/Astellas, Johnson & Johnson/Basilea and Forest/Astrazeneca/Takeda Will Drive Modest Growth in the MRSA Drug Market Through 2018
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Aug. 31, 2015  Asterias Biotherapeutics, Inc. (NYSE ... emerging field of regenerative medicine, today announced that ... Chicago -based Rush University Medical Center ... of escalating doses of AST-OPC1 (oligodendrocyte progenitor cells) ... complete cervical spinal cord injury (SCI). This represents ...
(Date:8/31/2015)... WOODCLIFF LAKE, N.J. and STAMFORD, ... the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., and ... into a worldwide collaboration agreement for the development and ... a dual orexin receptor antagonist entering Phase III clinical ... Under the terms of the agreement, Eisai and Purdue ...
(Date:8/31/2015)... Australia , Aug. 31, 2015 Bionomics ... discovery and development of innovative therapeutics for the treatment ... cancer, today announced that its BNC101 IND submission has ... (FDA). Bionomics plans to initiate a Phase 1 clinical ... patients with metastatic pancreatic cancer prior to 31 December ...
Breaking Medicine Technology:Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 4Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 5Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 6Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 2Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 3Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 4Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 5Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 2Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 3Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 4
(Date:9/1/2015)... ... ... September is Baby Safety Month, and Lightning Labels wants to ... ones' safety top of mind at all times. , Sponsored by the Juvenile Products ... JPMA's Baby Safety Zone website, this year's theme is A Room with A Safe ...
(Date:9/1/2015)... ... September 01, 2015 , ... The ... Systems, has become a leader in podiatric, surgical and wound care ... Superwounds Conferences place top national speakers at the podium and across the table ...
(Date:8/31/2015)... ... September 01, 2015 , ... ... the release of ten hours of new premium on-demand video Evidence Based ... , Athletic Trainers certified before 2014 must complete 50 CEUs before December 31, ...
(Date:8/31/2015)... (PRWEB) , ... September 01, 2015 , ... ... to eliminate chronic back pain – once required a long, arduous recovery. However, ... hospital stay, less pain, less blood loss and minimal muscle damage. These advantages ...
(Date:8/31/2015)... ... 31, 2015 , ... Sculpted Contours Luxury Medical Aesthetics proudly announces that Kathy ... by Modern Luxury’s The Atlantan Magazine. , This award for the Sculpted ... Her idea and vision to bring to Atlanta a true luxury experience in ...
Breaking Medicine News(10 mins):Health News:Lightning Labels Can Help Make A Difference This Baby Safety Month 2Health News:Lightning Labels Can Help Make A Difference This Baby Safety Month 3Health News:PRESENT e-Learning Systems Announces their 2016 Podiatry and Wound Care Medical Education Conference Schedule 2Health News:Evidence Based Practice Courses: CEUs For Athletic Trainers Just Released 2Health News:Minimally Invasive Spinal Fusions Squash Back Pain without Arduous Recovery 2Health News:Minimally Invasive Spinal Fusions Squash Back Pain without Arduous Recovery 3Health News:Minimally Invasive Spinal Fusions Squash Back Pain without Arduous Recovery 4Health News:Sculpted Contours Owner Selected One of Atlanta's Women of Power and Influence by Modern Luxury's The Atlantan Magazine 2Health News:Sculpted Contours Owner Selected One of Atlanta's Women of Power and Influence by Modern Luxury's The Atlantan Magazine 3
... may have a way to make the powerful cancer drug ... some cancers. The chemotherapeutic agent used in combination with other ... or failure in about 30 percent of users, although the ... to protect the kidneys is advise patients to drink more ...
... News) -- A man,s heart disease risk after the age of ... body size and placenta size when he was born, a new ... lifetime nutrition and the early growth of her child," study lead ... University of Southampton in the United Kingdom, said in a news ...
... study published in the journal Clinical Cardiology ... resynchronization therapy (CRT) improves patients, libido, erectile dysfunction, and ... complex clinical syndrome characterized by fatigue and exercise intolerance. ... CRT, which is a type of pacemaker that paces ...
... Physicians can help their patients follow prescribed ... chronic disease management by using a three-pronged ... the University of California, Riverside, Texas State University-San ... The Information-Motivation-Strategy (IMS) Model developed after ...
... at the University of Southern California have pinned down ... survival trait: our ability to comprehend a sceneeven one ... The key is to process the interacting objects ... according to corresponding author Irving Biederman, professor of psychology ...
... hurdles in obtaining an appointment for care with an ... of Medicine at the University of Pennnsylvania that will ... meeting of American Society of Clinical Oncology (Abstract #6128). ... an appointment, with just 22 percent of them obtaining ...
Cached Medicine News:Health News:Cause and potential treatment found for cancer drug's kidney toxicity 2Health News:Male Heart Disease May Be Linked to Mom's Lifetime Nutrition 2Health News:Researchers develop strategy to improve patient adherence 2Health News:Researchers develop strategy to improve patient adherence 3Health News:USC study locates the source of key brain function 2Health News:Two-thirds of newly diagnosed cancer patients unable to obtain oncology appointments 2
... KeraCel Ophthalmic Products are ... formulation of lint-free MEROCEL polyvinyl ... configured to be beneficial to ... being absorbent, and yet firm ...
... Products provide the surgeon ... products for unparalleled fluid ... of fine microsurgical instruments. ... is highly absorbent, fast ...
... Merocel Ophthalmic Products provide ... fiber free products for ... safe cleaning of fine ... Merocel material is highly ...
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
Medicine Products: